Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
As of today, Neurocrine(NBIX) shares are valued at $136.18. The company's market cap stands at 13.58B, with a P/E ratio of 32.52.
During the trading session on 2026-01-24, Neurocrine(NBIX) shares reached a daily high of $138.74 and a low of $135.41. At a current price of $136.18, the stock is +0.6% higher than the low and still -1.8% under the high.
Trading volume for Neurocrine(NBIX) stock has reached 1.11M, versus its average volume of 1.14M.
The stock's 52-week range extends from a low of $84.23 to a high of $160.18.
The stock's 52-week range extends from a low of $84.23 to a high of $160.18.
NBIX News
Neurocrine Biosciences (NBIX) shares are in focus after new clinical data showed its VMAT2 inhibitor INGREZZA achieved higher target occupancy and greater poten...
UBS lowered the firm’s price target on Neurocrine (NBIX) to $178 from $188 and keeps a Buy rating on the shares. Crenessity momentum could break the stock out o...
Analyst ratings
87%
of 30 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.